{"preliminary_commentary":{"by_channel":{"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05009836\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SANOVO","nct_id":"NCT05009836","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sanovo-nct05009836. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SANOVO","arms":[{"description":"Savolitinib 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally+ Osimertinib 80 mg QD orally ( every 3 weeks)","label":"Savolitinib + Osimertinib","type":"EXPERIMENTAL"},{"description":"Placebo 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally+ Osimertinib 80 mg QD orally ( every 3 weeks)","label":"Placebo + Osimertinib","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-05-30","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":412,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Savolitinib","otherNames":["HMPL-504"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Osimertinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-22","lead_sponsor":"Hutchmed","official_title":"A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-05-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PFS","timeFrame":"17 months after the last patient enrolled"}],"references":[],"start_date":{"date":"2021-09-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","url":"https://clinicaltrials.gov/study/NCT05009836"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sanovo-nct05009836"}